Free Trial
ETR:BIO

Biotest Aktiengesellschaft (BIO) Stock Price, News & Analysis

Biotest Aktiengesellschaft logo
€42.80 0.00 (0.00%)
As of 04/2/2025

About Biotest Aktiengesellschaft Stock (ETR:BIO)

Key Stats

Today's Range
€42.60
€42.80
50-Day Range
€40.80
€42.80
52-Week Range
€40.40
€43.40
Volume
700 shs
Average Volume
1,927 shs
Market Capitalization
$847.01 million
P/E Ratio
10.31
Dividend Yield
0.09%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.

Remove Ads
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

BIO Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Biotest Aktiengesellschaft (BIO.DE)
Biotest Aktiengesellschaft (BIESF)
Biotest Aktiengesellschaft (BIO3.F)
See More Headlines

BIO Stock Analysis - Frequently Asked Questions

Biotest Aktiengesellschaft's stock was trading at €41.20 at the beginning of the year. Since then, BIO stock has increased by 3.9% and is now trading at €42.80.
View the best growth stocks for 2025 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biotest Aktiengesellschaft investors own include GSK (GSK), Invitae (NVTA), Adaptive Biotechnologies (ADPT), ADMA Biologics (ADMA), Analog Devices (ADI), Adaptimmune Therapeutics (ADAP) and Axcelis Technologies (ACLS).

Industry, Sector and Symbol

Stock Exchange
ETR
Sector
Medical
Industry
Biotechnology
Sub-Industry
Measuring And Control Equipment
Current Symbol
ETR:BIO
CIK
N/A
Fax
N/A
Employees
8,200
Year Founded
N/A

Profitability

Trailing P/E Ratio
10.31
Forward P/E Ratio
356.67
P/E Growth
N/A
Net Income
$164.40 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$781.30 million
Cash Flow
€1.38 per share
Price / Cash Flow
31.04
Book Value
€14.18 per share
Price / Book
3.02

Miscellaneous

Free Float
N/A
Market Cap
$847.01 million
Optionable
Not Optionable
Beta
0.24
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (ETR:BIO) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners